Literature DB >> 18928579

Cellular and molecular interactions in coinfection with hepatitis C virus and human immunodeficiency virus.

Barbara Roe1, William W Hall.   

Abstract

Coinfection with hepatitis C virus (HCV) and human immunodeficiency virus (HIV) is associated with increased HCV replication and a more rapid progression to severe liver disease, including the development of cirrhosis and hepatocellular carcinoma. In this review, we discuss the current understanding of the pathogenesis of HCV/HIV coinfection and the cellular and molecular mechanisms associated with the accelerated course of liver disease. The strength and breadth of HCV-specific T-cell responses are reduced in HCV/HIV-coinfected patients compared with those infected with HCV alone, suggesting that the immunosuppression induced by HIV compromises immune responses to HCV. HCV is not directly cytopathic, but many of the pathological changes observed in the liver of infected patients are a direct result of the intrahepatic antiviral immune responses. Apoptosis also has a role in HCV-mediated liver damage through the induction of apoptotic pathways involving the host immune response and HCV viral proteins. This review summarises the evidence correlating the role of cell-mediated immune responses and apoptosis with liver disease progression in HCV/HIV-coinfected patients.

Entities:  

Mesh:

Year:  2008        PMID: 18928579     DOI: 10.1017/S1462399408000847

Source DB:  PubMed          Journal:  Expert Rev Mol Med        ISSN: 1462-3994            Impact factor:   5.600


  17 in total

1.  The hepatitis C virus 5'UTR genomic region remains highly conserved under HAART: a 4- to 8-year longitudinal study from HCV/HIV co-infected patients.

Authors:  Franco Moretti; Federico Bolcic; Lilia Mammana; Maria Belen Bouzas; Natalia Laufer; Jorge Quarleri
Journal:  AIDS Res Hum Retroviruses       Date:  2010-05       Impact factor: 2.205

Review 2.  Pathogen-pathogen interaction: a syndemic model of complex biosocial processes in disease.

Authors:  Merrill Singer
Journal:  Virulence       Date:  2010 Jan-Feb       Impact factor: 5.882

3.  A case of severe acute hepatitis C and delayed antibody production due to rituximab therapy.

Authors:  Masaaki Hiura; Ryo Onizuka; Ryoichi Narita; Shintaro Abe; Akinari Tabaru; Masaru Harada
Journal:  Clin J Gastroenterol       Date:  2010-09-16

Review 4.  HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies.

Authors:  Eva A Operskalski; Andrea Kovacs
Journal:  Curr HIV/AIDS Rep       Date:  2011-03       Impact factor: 5.071

Review 5.  Advances in sexually transmitted infections of the gastrointestinal tract.

Authors:  Siew C Ng; Brian Gazzard
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-08-25       Impact factor: 46.802

Review 6.  Virologic and immunologic aspects of HIV-hepatitis C virus coinfection.

Authors:  Kara W Chew; Debika Bhattacharya
Journal:  AIDS       Date:  2016-10-23       Impact factor: 4.177

7.  The impact of IL28B genotype on the gene expression profile of patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin.

Authors:  Zobair M Younossi; Aybike Birerdinc; Mike Estep; Maria Stepanova; Arian Afendy; Ancha Baranova
Journal:  J Transl Med       Date:  2012-02-07       Impact factor: 5.531

Review 8.  Co-infections as Modulators of Disease Outcome: Minor Players or Major Players?

Authors:  Priti Devi; Azka Khan; Partha Chattopadhyay; Priyanka Mehta; Shweta Sahni; Sachin Sharma; Rajesh Pandey
Journal:  Front Microbiol       Date:  2021-07-06       Impact factor: 5.640

Review 9.  Hepatitis C virus infection in the immunocompromised host: a complex scenario with variable clinical impact.

Authors:  Anna Linda Zignego; Carlo Giannini; Laura Gragnani; Alessia Piluso; Elisa Fognani
Journal:  J Transl Med       Date:  2012-08-03       Impact factor: 5.531

10.  Silibinin inhibits HIV-1 infection by reducing cellular activation and proliferation.

Authors:  Janela McClure; Erica S Lovelace; Shokrollah Elahi; Nicholas J Maurice; Jessica Wagoner; Joan Dragavon; John E Mittler; Zane Kraft; Leonidas Stamatatos; Leonidis Stamatatos; Helen Horton; Stephen C De Rosa; Robert W Coombs; Stephen J Polyak
Journal:  PLoS One       Date:  2012-07-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.